



Reducing Cardiovascular Risk by Lipid Modification

**Live
Webinar**

An inspiring webinar on lipid modification was held on 2nd November, 2020, featuring the insights of veteran specialists in cardiology and neurology.

The use of PCSK9 inhibitors in Hong Kong



Prof. Tse Hung Fat

- Chair Professor of Cardiovascular Medicine & William MW Mong Professor in Cardiology, Department of Medicine, The University of Hong Kong
- Specialist in Cardiology, Queen Mary Hospital

- Despite the use of statin and ezetimibe, a significant proportion of very high-risk patients cannot achieve LDL-C goal, especially HeFH subset
- Goal-inhibiting statin intolerance (partial intolerance) and goal-inhibiting statin resistance (both Non-FH and FH patients) affect substantial numbers of patients
- PCSK9 inhibitor is an effective non-statin therapy to achieve LDL-C goal in very high-risk patients with statin intolerance

The use of PCSK9 inhibitors in statin-associated immune-mediated necrotizing myopathy in Hong Kong Chinese population: A case series



Dr. Gao Yuan Gene

- Specialist in Neurology, Queen Mary Hospital

- IMNM can be induced by statin and HMGR-IMNM is not uncommon
- Early recognition and aggressive treatment of HMGR-IMNM are important
- A clear indication of using PCSK9 inhibitor for treating these patients
- Conduct gene testing to screen HMGR-IMNM patients and start PCSK9 inhibitor treatment if positive

Patients with the Highest Urgency to be Treated



Prof. Shaun Goodman

- Associate Head, Division of Cardiology, St Michael's Hospital, Canada
- Professor and Heart & Stroke Foundation of Ontario (Polo) Chair, Department of Medicine, University of Toronto

For more details on the practical use of PCSK9 inhibitors on very high-risk patients explained by Prof. Goodman, scan the QR code to revisit the webinar.



FH=familial hypercholesterolemia. HeFH=heterozygous familial hypercholesterolemia. HMGR=3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. HMGR-IMNM=statin-induced anti-HMGR autoantibody associated immune-mediated necrotizing myopathy. IMNM=immune-mediated necrotizing myopathy. LDL-C=low-density lipoprotein cholesterol. PCSK9=proprotein convertase subtilisin/kexin type 9.